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Induction of anti-GBM nephritis in rats by recombinant a3(IV)NC1
and a4(IV)NC1 of type IV collagen. The capability of the noncollagenous
(NC1) domains of the six a chains of human type IV collagen to induce
anti-glomerular basement membrane (GBM) nephritis in WKY rats was
determined. This was accomplished by using recombinant technology to
express the six NC1 domains in mammalian 293 cells and to purify the
proteins using an anti-Flag affinity column. All rats injected with
a3(IV)NC1 and a4(IV)NC1 developed proteinuria and hematuria. Rats
injected with a5(IV)NC1 developed mild hematuria, whereas rats injected
with the a1(IV)NC1, a2(IV)NC1 and a6(IV)NC1 domains developed
neither proteinuria nor hematuria. The renal lesions induced by
a3(IV)NC1 and a4(IV)NC1 domains were characteristic of those in
patients with anti-GBM nephritis and Goodpasture syndrome. The exper-
imental nephritis is mediated by anti-basement membrane antibodies that
are targeted to a3(IV)NC1 and a4(IV)NC1 domains and which bind to
the glomerular basement membrane. The uniqueness of the a3(IV)NC1
and a4(IV)NC1 domains, among the six NC1 domains, to induce severe
anti-GBM disease may relate to the accessibility of epitopes in the GBM
for binding of antibody. The pathogenicity of the a4(IV)NC1 antibodies
establishes a conundrum because the pathogenic antibodies in patients are
not targeted to the a4(IV)NC1, but are targeted to the a3(IV)NC1
domain in anti-GBM nephritis and to the a3(IV)NC1 and a5(IV)NC1
domains in Alport post-transplant anti-GBM nephritis.
Anti-basement membrane antibodies can cause glomerulone-
phritis (anti-GBM nephritis) or pulmonary hemorrhage by them-
selves, or Goodpasture syndrome when they occur together. The
immunopathogenic role of anti-GBM antibodies was established
when these antibodies were found bound in glomeruli as well as in
the circulation, and could transfer glomerulonephritis to nonhu-
man primates or to renal allografts [1–3]. The target autoantigen
in GBM has been identified as the a3(IV) collagen [4, 5], one of
the six genetically-distinct chains that comprise type IV collagen
[6]. In a recent study of 58 patients, the a3(IV) chain was found
to be the common autoantigen in anti-GBM nephritis and Good-
pasture syndrome [7]. The anti-GBM antibodies of all patients
reacted with the a3(IV)NC1 domain (85% exclusively). Addi-
tional limited reactivity with the a1(IV)NC1 and a4(IV)NC1 was
found in 15% and 3% of the patients, respectively. In a study of 10
patients, using E. coli fusion proteins of the six a(IV)NC1
domains, all showed reactivity to a3(IV)NC1 domain and several
sera showed additional reactivity to a2(IV), a4(IV) or
a6(IV)NC1 domains [8]. These results strongly suggested that
a3(IV)NC1 antibodies are the pathogenic ones causing the dis-
ease in all patients. Potentially, antibodies to the other domains
may also be pathogenic.
A causal relationship between anti-type IV collagen antibodies
and renal and pulmonary lesions has been suggested from several
studies using experimental animal models. First, anti-GBM ne-
phritis was induced in WKY rats by injection of collagenase
solubilized fractions of bovine [9], human [10] and rat [11] renal
basement membranes. The nephritogenic fraction is now know to
contain the NC1 domains of the six a chains (a1 to a6) of type IV
collagen, whereas the non-nephritogenic fraction contained only
the NC1 domains of the a1(IV) and a2(IV) chains, suggesting
that the NC1 domain of one or more of the a3(IV)-a6(IV) chains
is nephritogenic. Also, anti-GBM nephritis was induced in rats by
injection of synthetic peptides derived from the human NC1
domain of the a3(IV), a4(IV) and a5(IV) chains [12]. Second,
denatured a3(IV) dimers (bovine) were shown to induce anti-
a3(IV) antibodies that cause pulmonary and renal lesions in
rabbit [13]. Overall these studies indicate that the NC1 domain of
one or more of the a3(IV) to a6(IV) chains has the capability to
induce pathogenic antibodies causing renal and pulmonary le-
sions.
In the present study, the capability of NC1 domains of each of
the six a chains of human type IV collagen to induce renal lesions
was unambiguously determined. This was accomplished using
recombinant technology to express and purify the six NC1 do-
mains and using WKY rats as the animal model. The findings
showed that a3(IV)NC1 and a4(IV)NC1 proteins induced severe
nephritis, mimicking the organ-specific form of human anti-GBM
nephritis.
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METHODS
Recombinant proteins of a(IV)NC1
The recombinant human a(IV) NC1 domain proteins [r-a(IV)
NC1] were expressed as fusion proteins containing a Flag se-
quence peptide, DYKDDDDK (Kodak IBI systems, New Haven,
CT, USA). A modified eukaryotic expression vector derived from
pRc/CMV (Invitrogen, San Diego, CA, USA) was used to express
chimeric cDNAs in a mammalian expression system, human
kidney 293 cells (ATCC 1573-CRL). The expression vectors for
a3(IV)NC1, a4(IV)NC1 and a5(IV)NC1 were constructed by
PCR amplification of the genes from plasmids pDSa3 [14],
MM19-14 [15] and MD-6 [16], respectively, using the following
primers: 59GAT ATG CTA GCC GAC TAC AAG GAC GAC
GAT GAC AAA CGT GGA GAC39 and 59TAC ATA GGG
CCC TCA GTG TCT TTT CTT CAT GCA C39 for a3(IV)NC1;
59ATA ATG CTA GCC GAC TAC AAG GAC GAC GAT GAC
AAG CCT GGA TAC CTC GGT GGC TTC C39 and 59GCC
GAG GGC CCC TAG CTA TAC TTC ACG CAG39 for
a4(IV)NC1; 59T GGT CCG CTA GCT GAC TAC AAG GAC
GAC GAT GAC AAA GGT CCC CCT GG39 and 59TAG AAT
AGG GCC CTC TAG ATG CAT GCT CGA39 for a5(IV)NC1.
The construction of the expression vectors for a1(IV)NC1,
a2(IV)NC1 and a6(IV) NC1 domains was accomplished by PCR
amplification of the genes from a commercial cDNA library
(ClonTech, Palo Alto, CA, USA) using the following primers,
respectively: 59GCT AGC ATC TGT TGA TCA CGG CTT CC39
and 59CCG CGG TAG CTG AGT CAG GCT TCA TTA TG39
for a1(IV)NC1; 59GCT AGC CGT CAG CAT CGG CTA CCT
CC39 and 59GGG CCC TGG CAC GCG CCG GCT CAC AGG
39 for a2(IV)NC1; 59GCT AGC GAG CAT GAG AGT GGG
CTA CAC G39 and 59GGG CCC GTG GCA GGT GCC ACC
CTA CAG GC39 for a6(IV)NC1. The primers for a1, a2 and
a6(IV)NC1 domains were designed based in the published se-
quences for human type IV collagen [17–19], respectively. The
secreted proteins carried the Flag sequence fused to the amino
terminus of the respective full length NC1 domain. The proteins
in the cell culture medium where purified by a single affinity
chromatographic step using anti-Flag agarose columns. The re-
combinant proteins were characterized by SDS-PAGE and West-
ern blotting, using 4 to 22% gradient gels. Western blotting and
one dimensional electrophoresis analysis were done as described
by Burnette [20] and Laemmli [21], respectively. Molecular weight
markers proteins were from BioRad (Hercules, CA, USA).
Animals
Female WKY/NCrj inbred rats purchased from Charles River
Japan, Inc. (Yokohama, Japan) were used. Rats (8 weeks of age)
were housed in polycarbonate plastic cages containing wood
shavings as bedding. The animal experiments in the present study
were conducted according to the Guidelines for Laboratory Animal
Experiments of Shigei Medical Research Institute.
The rats were injected via hind footpads with an emulsion
containing 50 mg of the protein and an equal amount of Freund’s
complete adjuvant (FCA). Fifteen-hour urine (from 6 p.m. to
9 a.m.) was collected weekly for six weeks after injection. Rats
were sacrificed three or six weeks after injection and samples of
renal tissue and sera were obtained.
Analysis of rat sera for antibodies against a(IV)NC1 domains
The presence and specificity of antibodies for NC1 domains in
the sera of immunized rats were investigated by ELISA. Dispos-
able 96-well plates were coated overnight with 25 ng of each
recombinant Flag-NC1 protein dissolved in 200 ml of 0.05 M
sodium carbonate, pH 9.5 (coating buffer). The plates were
washed with 0.15 M NaCl/0.05% Tween-20 (washing solution) and
subsequently incubated with 1% casein in incubation buffer (50
mM Tris pH 7.4) for one hour at room temperature. The plates
were then incubated with 1:100, 1:500 and 1:1000 dilutions of the
rat sera for four hours, at room temperature. After washing again,
the secondary antibody goat anti-rat IgG-AP conjugated (1:3000),
was added. After incubation at room temperature for two hours,
the plates were washed and developed by adding Sigma 104
phosphatase substrate solution (1 mg/ml in diethanol amine, pH
8.9). The absorbance at 410 nm was measured in a Dynatech MR
4000 plate reader.
Before application to the plate, the rat sera dilutions were
incubated, overnight at 4°C, with Flag peptide, final concentration
of 5 mg/ml, in order to block potential cross-reactivity by anti-Flag
antibodies. The sera was obtained at six weeks for the rats injected
with a1, a2, a3, a5 and a6 proteins and at three weeks for rats
injected with a4 protein.
Fig. 1. Analysis of r-a(IV)NC1 proteins. (A) SDS-PAGE analysis of
recombinant a(IV)NC1 proteins on 4 to 22% gels, and stained with
Coomassie brilliant blue. (B) Western blot analysis with chain-specific
monoclonal antibodies, as indicated in the Methods section. Approxi-
mately 0.5 mg of each protein was loaded per lane.
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Urinary analysis, histological examination and
immunofluorescence studies
Urine was assayed for proteinuria by a modified method using
sulfosalicylic acid [22] and for hematuria by test paper (Hema-
Combistix; Miles-Sankyo, Tokyo, Japan). Samples of renal tissue
were fixed in Dubosq-Brazil fixative, embedded in paraffin, sec-
tioned at 3 mm, and stained with hematoxylin and eosin, periodic
acid-Schiff, and periodic acid-methenamine-silver (PAM). For the
immunofluorescence study, 4-mm cryostat sections of the kidney
were stained with FITC-conjugated goat antibody against rat IgG
and C3 (Cappel Lab., USA).
RESULTS
Characterization of the r-a(IV)NC1 proteins
The r-a(IV)NC1 proteins were prepared by expression of the
cDNAs in 293 cells, as a fusion proteins containing a Flag
sequence. The proteins were purified from the cell culture me-
dium by affinity chromatography on anti-Flag column. Analysis by
SDS-PAGE (Fig. 1A) shows that the NC1 domains were ex-
pressed as monomeric proteins with molecular weight ranging
from 26 kDa to 28 kDa. The apparent molecular weight varies
among the domains because the a1, a2 and a6(IV)NC1 domains
begin with the first amino acid of the non-collagenous sequence,
while a3, a4 and a5(IV)NC1 domains contain additional amino
acids from the collagenous domain. The molecular weights also
differ slightly from the NC1 domains obtained by collagenase
digestion of GBM because the recombinant domain contain an
additional flag sequence and the collagenase cleavage sites vary
with the NC1 domain [23]. The identity of the expressed proteins
was assessed by Western blot analysis using chain-specific mono-
clonals antibodies [24] (Fig. 1B). These domains, expressed in the
mammalian cells, exhibit the behavior of native proteins based
upon physicochemical properties (manuscript in preparation).
Effect of the r-a(IV)NC1 domains on renal function
The time course of hematuria and urinary protein of rats after
the injection with the recombinant NC1 domains are shown in
Figure 2. All six rats injected with a3(IV)NC1 or a4(IV)NC1 and
four rats injected with a5(IV)NC1 showed hematuria. Rats in-
jected with a1(IV)NC1, a2(IV)NC1, or a6(IV)NC1 domains
showed no hematuria. Proteinuria was present in all rats injected
with either a3(IV)NC1 or a4(IV)NC1 domains and in one rat
injected with a5(IV)NC1 domain. Proteinuria was defined as over
10.0 mg of urinary protein/15 hours because the control rats
showed a range of 1.3 to 4.4 mg/15 hours. Notably, heavy
proteinuria (over 100 mg/15 hr) was observed in all rats injected
with a3(IV)NC1 and a4(IV)NC1.
Fig. 2. Time course of urinary protein secretion of rats injected with recombinant proteins of the six aNC1 domains of human type IV collagen. The
protein in the urine collected weekly after injection was measured as indicated in the Methods section. The different lines represent individual animals
in each group: (E) without hematuria; (F) with hematuria. The rats injected with a4(IV)NC1 protein were sacrificed three weeks after the injection
because of emacination by severe glomerulonephritis.
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Fig. 3. Specificity of circulating antibodies elicited by the recombinant a(IV)NC1 proteins. Plasma was obtained at six weeks after injection with a1,
a2, a3, a5 and a6 proteins and three weeks for the a4 protein. The sera of 4 to 5 rats of each group injected with one of the six proteins was analyzed
by ELISA to determine the titer and specificity against each of the six a(IV)NC1 proteins. Each panel represents rats injected with one of the six
a(IV)NC1 proteins. The sera was a 1:100 dilution. The ELISA reading for control sera was ,0.1. The titer for antibodies elicited by a2(IV)NC1 protein
was not significantly above control.
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Fig. 4. Histology study of rat kidneys after
injection with r-a(IV)NC1 proteins. (A) Six
weeks after injection with a3(IV)NC1 protein.
(B) Three weeks after injection with
a4(IV)NC1 protein. (C) Six weeks after
injection with a5(IV)NC1. Severe damage such
as lobulation and sclerosis of capillary tufts, and
crescent formation were found in A and B.
Mild adhesion and endocapillary
hypercellularity were found in C. PAM staining
3160. Rats were injected with 50 mg of the
recombinant protein.
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Fig. 5. Direct immunofluorescence of rat kidneys with FITC-anti-rat IgG. (A) A faint linear staining observed along the GBM of a rat injected with
the a3(IV)NC1 protein six weeks after injection (3280). (B) Intense linear staining was observed along the GBM and TBM of a rat injected with
a4(IV)NC1 protein three weeks after injection (3140).
Analysis of antibodies induced by the r-a(IV)NC1 domains
The titer and specificity of circulating antibodies induced by
immunization with the six r-a(IV)NC1 domains were analyzed by
ELISA (Fig. 3). All domains, except a2(IV)NC1, elicited antibody
production but to varying titers. The highest titer was against the
a3(IV) and a5(IV)NC1 proteins and the lowest against the
a1(IV)NC1 protein. Each NC1 protein elicited the production of
antibodies that cross-reacted to varying extents with the other
NC1 proteins as would be predicted because of their high degree
of sequence homology [6].
Histological analysis of renal tissues
Rats having severe proteinuria, induced by a3(IV)NC1 and
a4(IV)NC1, exhibited major abnormalities in 98 to 100% of the
glomeruli, including endocapillary hypercellularity of mononu-
clear cells, capsular adhesion, lobulation and sclerosis of capillary
tufts, and crescent formation (Fig. 4). Rats with moderate pro-
teinuria with hematuria, induced by a5(IV)NC1 protein, also
showed mild histological changes in the glomeruli such as endo-
capillary hypercellularity and capsular adhesion, with 23% of the
glomeruli being abnormal. In two rats, having hematuria but no
proteinuria, the percentage of abnormal glomeruli ranged from
0.7 to 5.6%, and those of the other three rats having neither
hematuria nor proteinuria ranged from 0 to 0.8%. In contrast, rats
with no proteinuria nor hematuria, injected with the a1(IV)NC1,
a2(IV)NC1, or a6(IV)NC1 had no glomerular abnormalities. The
nephritic rats, induced by a3(IV)NC1 and a4(IV)NC1 domains,
also showed IgG bound to the GBM (Fig. 5). Rats immunized
with a1(IV)NC1, a2(IV)NC1, a5(IV)NC1 and a6(IV)NC1
showed no antibody binding to the GBM. No C3 deposition was
detected along the GBM in any of the rats.
DISCUSSION
This study reveals that the a3(IV)NC1 and a4(IV)NC1 do-
mains, among the six NC1 domains of type IV collagen, possess
the unique capability to induce severe anti-GBM nephritis upon
injection into WKY rats. The a5(IV)NC1 domain is weakly
nephrogenic causing mild hematuria but the anti-a5(IV)NC1
antibodies do not bind to the GBM to the extent that they can be
detected by immunofluorescence staining. The strong pathogenic-
ity of only the a3(IV)NC1 and a4(IV)NC1 antibodies represents
and enigma because the GBM contains five (a1 to a5) of the six
a chains [24]. The pathogenicity possibly relates to the accessibil-
ity of the epitope(s) that is required for binding to GBM.
The nephritogenicity of a3(IV)NC1 and a4(IV) NC1 domains
advance a molecular explanation for previous landmark studies,
including the demonstration that the passive transfer of GP
antibodies into monkeys produces nephritis [3] and that sheep
immunized with large amounts of human GBM develop anti-
GBM nephritis [2, 25]. These findings also provide an explanation
for the anti-GBM nephritis in sheep and rats induced by human
GBM [26] and soluble bovine GBM [22], respectively.
The capability of both a3(IV)NC1 and a4(IV)NC1 domains to
elicit the production of pathogenic antibodies establishes a co-
nundrum with reference to human anti-GBM nephritis. First,
both a3(IV)NC1 and a4(IV)NC1 domains induce antibodies in
WKY rats that bind to GBM analogous to that of human
anti-GBM nephritis. Second, in patients with anti-GBM nephritis
and Goodpasture syndrome, the antibodies are exclusively tar-
geted to the a3(IV)NC1 domain, except in a few cases where they
are additionally targeted to other domains [7, 8]. Third, in patients
with Alport syndrome who develop post-transplant anti-GBM
nephritis, the anti-GBM alloantibodies are targeted to
a3(IV)NC1 [27, 28] and a5(IV)NC1 [29–32] but not to
a4(IV)NC1. Given the nephritogenicity of both a3(IV)NC1 and
a4(IV)NC1, one would predict that the anti-GBM alloantibodies,
elicited by the normal allograft, would be targeted to a4(IV)NC1
as well as a3(IV)NC1 because both are absent in Alport GBM [7,
29, 33] and both exist in the same triple helical molecule in normal
GBM [34]. Thus, any event that exposes a3(IV)NC1 to the
immune system would likely expose a4(IV)NC1 causing the
production of antibodies against both domains. However, this is
not the case because the human antibodies are directed against
a3(IV)NC1 and not a4(IV)NC1. The production of anti-a3(IV)
antibodies, but not anti-a4(IV) antibodies, may represent an
important clue for deciphering the mechanism that underlies the
etiology of anti-GBM nephritis and Goodpasture syndrome.
Potentially, the mechanism may result from molecular mimicry
wherein an unrelated foreign antigen could share a pathogenic
epitope with a3(IV)NC1 domain, but not a4(IV)NC1, and which
could engage the immune system to selectively produce anti-
a3(IV)NC1 antibodies.
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